A concise review of irradiation sequelae on the cardiovascular system in pulmonary malignancies

• Үндсэн зохиолчид: Omer Sager (Зохиогч), Murat Beyzadeoglu (Зохиогч), Ferrat Dincoglan (Зохиогч), Selcuk Demiral (Зохиогч), Bora Uysal (Зохиогч), Hakan Gamsiz (Зохиогч), Fatih Ozcan (Зохиогч), Onurhan Colak (Зохиогч), Bahar Dirican (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Journal of Surgery and Surgical Research - Peertechz Publications, 2020-06-15.
• Нөхцлүүд: Review Article
• Онлайн хандалт: Connect to this object online.

Тойм

<p>Pulmonary malignancies including Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) are frequent cancers and remain to be a leading cause of cancer related mortality worldwide. Radiation Therapy (RT) has an integral role in management of both SCLC and NSCLC. It may be used as the single definitive modality, as part of curative combined modality management, and also for salvage treatment or recurrent disease settings in selected patients. Nevertheless, radiation induced toxicity constitutes an important concern in radiotherapeutic management of pulmonary malignancies. Among the adverse effects of pulmonary irradiation, radiation induced cardiotoxicity deserves utmost consideration. Several studies consistently underscore the importance of minimizing heart exposure as much as possible to avoid untowards cardiac morbidity and mortality.</p><br><p>There have been substantial advances which contributed to improved radiotherapeutic management of SCLC and NSCLC including improved staging and target definition by incorporation of molecular imaging, automatic segmentation procedures, Image Guided Radiation Therapy (IGRT), Breathing Adapted Radiation Therapy (BART), Adaptive Radiation Therapy (ART), Intensity Modulated Radiation Therapy (IMRT). Nevertheless, there is room for further achievements. Proton therapy for management of lung cancer has been suggested as a relatively newer treatment modality with promising results. Unique characteristics of proton therapy may allow for improved cardiac sparing along with reduced integral dose. Future trials are warranted to shed light on contemporary management of pulmonary malignancies with optimal cardiac sparing and reduced irradiation sequelae. Herein, we provide a concise review of irradiation sequelae on the cardiovascular system in pulmonary malignancies.</p>

DOI

10.17352/2455-2968.000102